Aminosalicylates.

Abstract

Symptomatic diverticular disease has a high prevalence in countries with a western lifestyle. Besides antibiotics for acute diverticulitis there are no established medical interventions to prevent or to treat symptomatic diverticular disease. Due to its broad spectrum of anti-inflammatory activities, mesalazine is a candidate for the treatment of symptomatic diverticular disease. A review of the literature shows that randomized open studies using various treatment designs suggest a protective role of mesalazine in preventing recurrences of diverticulitis. Currently, 5 randomized placebo-controlled trials are active which will clarify the role of mesalazine to prevent recurrence of diverticulitis in the near future. Several randomized uncontrolled studies suggest that mesalazine improves symptoms in patients with symptomatic uncomplicated diverticular disease. The analysis of secondary end points from two randomized placebo-controlled trials suggests that mesalazine improves symptoms in diverticular disease although both studies failed to show a statistically significant advantage for mesalazine for the primary study end point. In segmental colitis associated with diverticulosis no prospective systematic studies are available. However, several case reports show a high efficacy of mesalazine in segmental colitis associated with diverticulosis.

• Authors: Volker Gross
• Journal: Digestive diseases (Basel, Switzerland) (Dig Dis) Vol. 30 Issue 1 Pg. 92-9 ( 2012) ISSN: 1421-9875 [Electronic] Switzerland
• PMID: 22572694 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2012 S. Karger AG, Basel.

Chemical References

• Aminosalicylic Acids
• Anti-Inflammatory Agents
• Mesalamine

Topics

• Aminosalicylic Acids (therapeutic use)
• Anti-Inflammatory Agents (therapeutic use)
• Colitis (complications, pathology)
• Diverticulitis, Colonic (complications, drug therapy, pathology, prevention & control)
• Humans
• Mesalamine (therapeutic use)
• Probiotics (therapeutic use)